LAMA2 related congenital muscular dystrophy
LAMA2-related congenital muscular dystrophy (LAMA2-CMD) is a genetic disorder characterized by muscle weakness and wasting, typically presenting at birth or in early infancy. It is caused by mutations in the LAMA2 gene, which encodes the laminin alpha-2 chain, a crucial component of the extracellular matrix in muscle tissue.
Pathophysiology[edit | edit source]
The LAMA2 gene provides instructions for making the laminin alpha-2 chain, which is part of the laminin-211 complex. This complex is essential for the structural integrity and function of muscle fibers. Mutations in LAMA2 disrupt the formation of laminin-211, leading to muscle fiber instability and degeneration.
Clinical Features[edit | edit source]
LAMA2-CMD is characterized by hypotonia (decreased muscle tone), muscle weakness, and delayed motor milestones. Affected individuals may also exhibit joint contractures, scoliosis, and respiratory difficulties.
Neurological Involvement[edit | edit source]
Some patients with LAMA2-CMD may present with white matter abnormalities in the brain, detectable via magnetic resonance imaging (MRI). These abnormalities do not typically correlate with significant cognitive impairment.
Diagnosis[edit | edit source]
Diagnosis of LAMA2-CMD is based on clinical evaluation, muscle biopsy, and genetic testing. Muscle biopsy may reveal a deficiency of laminin alpha-2 in the muscle tissue. Genetic testing can confirm mutations in the LAMA2 gene.
Management[edit | edit source]
There is currently no cure for LAMA2-CMD. Management focuses on supportive care, including physical therapy, orthopedic interventions, and respiratory support. Regular monitoring and multidisciplinary care are essential to address the various complications associated with the disorder.
Research and Animal Models[edit | edit source]
Research into LAMA2-CMD includes studies on animal models, such as mice, to better understand the disease mechanism and explore potential therapies.
Prognosis[edit | edit source]
The prognosis for individuals with LAMA2-CMD varies depending on the severity of the condition. While some individuals may achieve independent ambulation, others may require lifelong assistance and adaptive devices.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD